Synonyms: LY-686017 | LY686017 | VLY-686
Compound class:
Synthetic organic
Comment: Tradipitant is an orally available antagonist of the NK1 subtype of tachykinin receptors. It is Example 132 claimed in patent WO2003091226 [1]. Tradipitant is being investigated for potential anti-pruritic action in patients with atopic dermatitis.
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
No information available. |
Summary of Clinical Use |
Tradipitant has reached Phase 2 clinical trial for evaluation in patients with treatment-resistant pruritus associated with atopic dermatitis (see NCT02651714). In a non-inflammatory setting tradipitant (LY686017) is being investigated as a potential pharmacological agent for treating social anxiety disorder [3] and alcohol dependence [2]- these studies are also at Phase 2. |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT02651714 | Tradipitant in Treatment-resistant Pruritus Associated With Atopic Dermatitis | Phase 2 Interventional | Vanda Pharmaceuticals |